Company intelligence / Profile preview

Curzion Pharmaceuticals

California, United States

Ownership: Private
Development stage: Other

Overview

Curzion Pharmaceuticals was a clinical-stage biotech company focused on rare fibrotic diseases, particularly developing CZN001 (HZN-825), an oral selective LPAR1 antagonist. Phase 1 trials showed it was safe and well-tolerated; Phase 2a showed potential clinical benefit in dcSSc. The company was acquired before Phase 2b began.

Therapeutic areas: Rheumatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Sanofi (original discoverer, eligible for milestones and royalties)

Beyond the preview

Go deeper on Curzion Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curzion Pharmaceuticals.

Explore the full profile